The most popular melatonin product at your pharmacy is labelled 5mg or 10mg. The dose that leading chronobiologists actually recommend for circadian phase-shifting is 0.3–0.5mg. That is a tenfold to thirtyfold discrepancy — and understanding why it exists is one of the most actionable pieces of sleep science available to athletes.
The confusion arises from conflating two separate things: pharmacological sedation and circadian signal. Most of the melatonin products sold globally are optimised for the first — inducing sleepiness through a sedative effect. The second — actually shifting your body clock to a new schedule — requires something far more precise.
---
In 2000, Zeitzer and colleagues published a landmark dose-response study in the Proceedings of the National Academy of Sciences. Their controlled protocol measured the phase-advancing effect of exogenous melatonin at doses ranging from 0.02mg to 20mg. The finding was counterintuitive: 0.3mg was as effective as 3mg at advancing circadian phase when administered in the late afternoon before habitual sleep time. Higher doses did not improve phase-shifting efficacy — they only increased plasma concentration far beyond what receptors could productively bind.
The reason is receptor pharmacology. Melatonin acts on two primary receptor subtypes: MT1 (mediating sleep induction and circadian phase effects) and MT2 (involved in circadian rhythm entrainment in the suprachiasmatic nucleus). Both receptors become saturated at relatively low plasma concentrations. Once saturated, excess melatonin circulates without binding to an active site. More critically, prolonged exposure to supraphysiological concentrations initiates receptor desensitisation and downregulation — the classic pharmacological response to sustained receptor overstimulation.
---
The endogenous melatonin peak during the biological night is equivalent to approximately 0.1–0.3mg in systemic terms. Standard pharmacy doses of 5–10mg are therefore providing 10–100 times the physiological concentration. The body's own melatonin output is exquisitely timed and tightly regulated; flooding the system with a supraphysiological bolus disrupts the natural phase-shift signal rather than amplifying it.
Arendt (2009, Journal of Neuroendocrinology), one of the most cited researchers in chronobiology, has repeatedly noted that daytime drowsiness and morning grogginess — common complaints from melatonin users — are hallmarks of overdosing, not of effective circadian regulation. Brzezinski and colleagues (2005, SLEEP) in a comprehensive meta-analysis concluded that doses in the 0.3–5mg range were effective for sleep onset latency reduction, but noted no evidence of dose-dependent superiority above 0.5mg for phase-shifting purposes.
---
Formulation matters as much as dose. Sublingual melatonin achieves approximately 85% bioavailability due to direct absorption into the sublingual venous plexus, bypassing hepatic first-pass metabolism. Oral tablets average 33% bioavailability. If you are using oral tablets at 0.5mg, the effective dose absorbed is closer to 0.17mg — consider sublingual formulations if you want precision at low doses.
Formulation type also determines application: immediate-release melatonin is appropriate for phase-shifting (jet lag management, advancing sleep onset for early morning training blocks); sustained-release formulations are better suited for sleep maintenance issues where wake-after-sleep-onset is the primary problem. Using the wrong formulation for the wrong goal is another common source of sub-optimal outcomes.
For athletes dealing with evening competitions followed by early morning training sessions — a scheduling challenge extremely common across team sports, swimming heats, and multi-event athletics — the protocol supported by evidence is: 0.5mg immediate-release sublingual, administered 2–3 hours before desired sleep onset, combined with 30 minutes of 10,000 lux bright light therapy upon waking to anchor the circadian advance. This combination drives faster re-entrainment than melatonin alone.
---
The practical implication is to stop reaching for the 5mg bottle as a default. Start at 0.3–0.5mg and assess whether your sleep onset latency changes measurably within 3–5 days. If not, verify formulation and timing before increasing dose.
For athletes who want to calculate the optimal melatonin timing window based on their habitual sleep schedule, training schedule, and travel direction, the tool at winsport.uk/tools/health/melatonin-timing-calculator provides a personalised phase-shift protocol based on circadian science.
The question worth sitting with: are you accidentally blunting your own melatonin receptors every night with a pharmacy-sized dose — and has that contributed to the melatonin tolerance creep many athletes describe after long-term use?